LIDDS AB (publ) announced that Anders Månsson will assume the role of Chief Executive Officer for LIDDS, effective September 1st 2022 succeeding Nina Herne. Anders Månsson has broad experience from leading roles both in the biotech sector and in larger multinational pharmaceutical companies in an international setting over 25 years. His substantial experience in business development from serving as e.g VP & Head of Global Business Development in LEO Pharma will be important for LIDDS in driving the value of current and future collaborations.

Anders also has considerable experience from sales & marketing; he has been the Managing Director of a subsidiary in Ferring Pharmaceuticals, and he has headed a major global business unit in LEO Pharma. His experience also includes board-level and executive appointments in biotech companies, and most recently Anders was the CEO of RhoVac. Anders will join LIDDS September 1, 2022.

Nina will remain as CEO until Anders is in place to secure a smooth transition. Nina is leaving LIDDS due to personal reasons.